This video briefly summarizes the 12 month treat-and-extend use of aflibercept in neovascular age-related macular degeneration in naive patients presented at this year’s EURETINA congress, held in Copenhagen, Denmark (Thursday 8 September 2016, 09:06-09:12). A total of 169 eyes treated with aflibercept in a treat-and-extend regime with 1-year follow-up was examined. Investigators Barthelmes et al. from Switzerland found that after 1 year there was an average of +9.5 letter increase in visual acuity, mean visual acuity gains after the initial 6 months of treatment was recorded at +9.1 letters compared with +0.4 in the following 6 months. There was an overall mean of 7.3 injections over the 12 months with 4.6 injections in the first 6 months and 2.7 in the second 6 months. Mean number of visits was 7.8 over the 12 months, 4.8 visits in the first 6 months and 3.0 in the second 6 months. Injections were given in 86% of all visits within the 12-month follow-up period. The study demonstrated that eyes treated with aflibercept in routine clinical practice under a treat and extend regiment achieve good visual outcomes for the first 12 months while decreasing the burden of treatments and clinic visits compared to the pivotal monthly injection trials.